Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 173

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90

Open access
Lundgren, Karen, Zhang, Hong, Brekken, John, Huser, Nanni, Powell, Rachel E., Timple, Noel, Busch, David J., Neely, Laura, Sensintaffar, John L., Yang, Yong-ching, McKenzie, Andres, Friedman, Jessica, Scannevin, Robert, Kamal, Adeela, Hong, Kevin, Kasibhatla, Srinivas R., Boehm, Marcus F., Burrows, Francis J.·2009·Molecular Cancer Therapeutics

Abstract

Inhibition of heat shock protein 90 (Hsp90) results in the degradation of oncoproteins that drive malignant progression, inducing cell death, making Hsp90 a target of substantial interest for cancer therapy. BIIB021 is a novel, fully synthetic inhibitor of Hsp90 that binds competitively with geldanamycin in the ATP-binding pocket of Hsp90. In tumor cells, BIIB021 induced the degradation of Hsp90 client proteins including HER-2, AKT, and Raf-1 and up-regulated expression of the heat shock proteins Hsp70 and Hsp27. BIIB021 treatment resulted in growth inhibition and cell death in cell lines from a variety of tumor types at nanomolar concentrations. Oral administration of BIIB021 led to the degradation of Hsp90 client proteins measured in tumor tissue and resulted in the inhibition of tumor growth in several human tumor xenograft models. Studies to investigate the antitumor effects of BIIB021 showed activity on both daily and intermittent dosing schedules, providing dose schedule flexibility for clinical studies. Assays measuring the HER-2 protein in tumor tissue and the HER-2 extracellular domain in plasma were used to show interdiction of the Hsp90 pathway and utility as potential biomarkers in clinical trials for BIIB021. Together, these data show that BIIB021 is a promising new oral inhibitor of Hsp90 with antitumor activity in preclinical models.[Mol Cancer Ther 2009;8(4):921–9]

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-08-0758

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 173

Metadata

Authors
Lundgren, K., Zhang, H., Brekken, J., Huser, N., Powell, R. E., Timple, N., Busch, D. J., Neely, L., Sensintaffar, J. L., Yang, Y.-C., McKenzie, A., Friedman, J., Scannevin, R., Kamal, A., Hong, K., Kasibhatla, S. R., Boehm, M. F., & Burrows, F. J.
Venue
Molecular Cancer Therapeutics
Published
2009-04-01
Volume
8
Issue
4
Pages
921-929
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2150664181
Cited by
173
References
3
FWCI
5.28
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. https://app.cochat.ai/papers/10.1158/1535-7163.mct-08-0758
The paper
Lundgren, K., Zhang, H., Brekken, J., Huser, N., Powell, R. E., Timple, N., Busch, D. J., Neely, L., Sensintaffar, J. L., Yang, Y.-C., McKenzie, A., Friedman, J., Scannevin, R., Kamal, A., Hong, K., Kasibhatla, S. R., Boehm, M. F., & Burrows, F. J. (2009). BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-08-0758

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.